[ad_1]
Postpartum depression (PPD), which most commonly occurs within six weeks after giving birth, affects up to 20% of women. According to National Institutes of Health research, less than 16% of women with symptoms of postpartum depression receive treatment, and the condition can last for months if left untreated, interfering with family connectedness and mothers’ overall well-being.
In August 2023, Sage remedies It received FDA approval for Zurzuvae (zuranolone), the first oral treatment for postpartum depression. The only previous treatment, Zulresso, also developed by Sage, requires an intravenous infusion for 60 hours in a hospital and carries risks, including loss of consciousness.
Zurzuvae is a pill taken once daily for 14 days. Unlike traditional antidepressants, which can take weeks to begin symptom relief, Zurzuvae is remarkably fast-acting: In clinical trials, new mothers with postpartum depression showed significant improvement in symptoms within as little as three days of starting treatment.
With a price tag of $13,400, the Zurzuvae is expected to generate $200 million in sales.
[ad_2]
Source link
